Boukaache Y, Ferret ML, Khoukh VDK, Enache A, Iwaszkiw D, Bertin S, Bruno F. Evaluation of the efficacy of transdermal administration of maropitant in managing vomiting in cats. Open Vet J. 2022 Sep-Oct;12(5):618-621. doi:10.5455/OVJ.2022.v12.i5.4
HICKMAN, M.A., COX, S.R., MAHABIR, S., MISKELL, C., LIN, J., BUNGER, A. and McCALL, R.B. (2008), Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (CereniaTM) for the prevention of emesis and motion sickness in cats. Journal of Veterinary Pharmacology and Therapeutics, 31: 220-229. doi:10.1111/j.1365-2885.2008.00952.x
Kinobe RT, Miyake Y. Evaluating the anti-inflammatory and analgesic properties of maropitant: A systematic review and meta-analysis. Vet J. 2020 May-Jun;259-260:105471. doi:10.1016/j.tvjl.2020.105471
Quimby JM, Brock WT, Moses K, Bolotin D, Patricelli K. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial. Journal of Feline Medicine and Surgery. 2015;17(8):692-697. doi:10.1177/1098612X14555441
SEDLACEK, H.S., RAMSEY, D.S., BOUCHER, J.F., EAGLESON, J.S., CONDER, G.A. and CLEMENCE, R.G. (2008), Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. Journal of Veterinary Pharmacology and Therapeutics, 31: 533-537. doi:10.1111/j.1365-2885.2008.00991.x
While effective, Dad didn’t like the squeeze tube dispenser. He said getting a consistent dose was difficult, and given the potential adverse reactions, it was important to him to get an accurate dose. We much prefer the click-to-dose dispenser style for this reason.
References and resources
Buhles W, Quimby JM, Labelle D, Williams VS. Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. J vet Pharmacol Therap. 2018; 41: 644-651. doi:10.1111/jvp.12691
Fantinati M, Trnka J, Signor A, et al. Appetite-stimulating effect of gabapentin vs mirtazapine in healthy cats post-ovariectomy. Journal of Feline Medicine and Surgery. 2020;22(12):1176-1183. doi:10.1177/1098612X20916391
Ferguson LE, McLean MK, Bates JA, Quimby JM. Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011). Journal of Feline Medicine and Surgery. 2016;18(11):868-874. doi:10.1177/1098612X15599026
Ferro L, Ciccarelli S, Stanzani G, Nappi L, Angelini F, Leo C. Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre Retrospective Study. Animals. 2022; 12(2):155. doi:10.3390/ani12020155
Poole M, Quimby JM, Hu T, Labelle D, Buhles W. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. J vet Pharmacol Therap. 2019; 42: 179-188. doi:10.1111/jvp.12738
Quimby, J.M., Gustafson, D.L. and Lunn, K.F. (2011), The Pharmacokinetics of Mirtazapine in Cats with Chronic Kidney Disease and In Age-Matched Control Cats. J Vet Intern Med, 25: 985-989. doi:10.1111/j.1939-1676.2011.00780.x
Quimby JM, Lunn KF. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J. 2013 Sep;197(3):651-5. doi:10.1016/j.tvjl.2013.05.048
Quimby JM, Benson KK, Summers SC, et al. Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease. Journal of Feline Medicine and Surgery. 2020;22(4):376-383. doi:10.1177/1098612X19851303
Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia. American Journal of Hospice and Palliative Medicine®. 2010;27(2):106-110. doi:10.1177/1049909109345685
Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, Langston C, Lefebvre HP, White J, Quimby J. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016 Mar;18(3):219-39. doi:10.1177/1098612X16631234
We tried this, but it was so vile I threw a fit harder and harder each time until Dad gave up. Apparently some folks have had better luck putting the liquid into a gelatin capsule so kitty can’t taste it. We’re going to stick to mirtazapine.
Jensen J, Henik RA, Brownfield M, Armstrong J. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Am J Vet Res. 1997 May;58(5):535-40. doi:10.2460/ajvr.1997.58.05.535
Jung, S.W. and Kittleson, M.D. (2011), The Effect of Atenolol on NT-proBNP and Troponin in Asymptomatic Cats with Severe Left Ventricular Hypertrophy because of Hypertrophic Cardiomyopathy: A Pilot Study. Journal of Veterinary Internal Medicine, 25: 1044-1049. doi:10.1111/j.1939-1676.2011.0754.x
Macgregor JM, Rush JE, Rozanski EA, Boothe DM, Belmonte AA, Freeman LM. Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. Am J Vet Res. 2008 Jan;69(1):39-44. doi:10.2460/ajvr.69.1.39
Ogawa M, Kawamura A, Akabane R, Sakatani A, Miyakawa H, Hsu H-H, et al. Effects of ivabradine and atenolol on heart rate and heart rate variability in healthy cats over a 24 h period: a pilot study. Vet Rec Open. 2022; 9:e28. doi:10.1002/vro2.28
Quiñones M, Dyer DC, Ware WA, Mehvar R. Pharmacokinetics of atenolol in clinically normal cats. Am J Vet Res. 1996 Jul;57(7):1050-3. doi:10.2460/ajvr.1996.57.07.1050
Riesen, S.C., Schober, K.E., Cervenec, R.M. and Bonagura, J.D. (2011), Comparison of the Effects of Ivabradine and Atenolol on Heart Rate and Echocardiographic Variables of Left Heart Function in Healthy Cats. Journal of Veterinary Internal Medicine, 25: 469-476. doi:10.1111/j.1939-1676.2011.0705.x
Schober KE, Zientek J, Li X, Fuentes VL, Bonagura JD. Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy. J Vet Cardiol. 2013 Jun;15(2):93-104. doi:10.1016/j.jvc.2013.03.003
Keisuke SUGIMOTO, Takuma AOKI, Yoko FUJII, Effects of atenolol on left atrial and left ventricular function in healthy cats and in cats with hypertrophic cardiomyopathy, Journal of Veterinary Medical Science, 2020, Volume 82, Issue 5, Pages 546-552. doi:10.1292/jvms.19-0670
Waterman M (2018). Pharmacodynamic evaluation of beta-blockade associated with atenolol in healthy dogs. Master’s Thesis, Virginia Polytechnic Institute and State University. http://hdl.handle.net/10919/97339
“One cat was prescribed budesonide administered PO due to the presence of complete heart block with 4-chamber dilation and concerns for provoking heart failure; the clinician cited anecdotal evidence that budesonide might cause less plasma volume expansion than prednisolone. After steroid administration, NT-proBNP in this cat increased by 93% (707-1367 pmol/L). Four months after the study ended and while still receiving budesonide, the cat developed a large volume of abdominal effusion. The cause of effusion was not determined. At the time of writing, no other cats had developed signs consistent with CHF.” — Block CL, Oyama MA. Echocardiographic and biomarker evidence of plasma volume expansion after short-term steroids administered orally in cats. J Vet Intern Med. 2020 Jan;34(1):29-34. doi:10.1111/jvim.15678 (retrieved 2025-01-10)
Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2011 Jul;7(4):419-28. doi:10.1586/eci.11.34
Adrian D, Papich MG, Baynes R, Stafford E, Lascelles BDX. The pharmacokinetics of gabapentin in cats. J Vet Intern Med. 2018; 32: 1996-2002. doi:10.1111/jvim.15313
Buckley C, Griffin C, Anderson H, Moore SA. Presumed gabapentin-induced myoclonus in two cats. JFMS Open Rep. 2024 Nov 28;10(2):20551169241273634. doi:10.1177/20551169241273634
Di Cesare F, Negro V, Ravasio G, Villa R, Draghi S, Cagnardi P. Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses. Animals. 2023; 13(12):2045. doi:10.3390/ani13122045
Fantinati M, Trnka J, Signor A, et al. Appetite-stimulating effect of gabapentin vs mirtazapine in healthy cats post-ovariectomy. Journal of Feline Medicine and Surgery. 2020;22(12):1176-1183. doi:10.1177/1098612X20916391
Guedes AGP, Meadows JM, Pypendop BH, Johnson EG, Zaffarano B. Assessment of the effects of gabapentin on activity levels and owner-perceived mobility impairment and quality of life in osteoarthritic geriatric cats. J Am Vet Med Assoc. 2018 Sep 1;253(5):579-585. doi:10.2460/javma.253.5.579
Madan RD, Cenani A, Montgomery E, Azevedo T, Vernau KM, Brosnan RJ. Pregabalin produces similar effects as gabapentin for preanesthetic sedation in cats. J Am Vet Med Assoc. 2023 Dec 22;262(3):359-363. doi:10.2460/javma.23.09.0493
Quimby JM, Lorbach SK, Saffire A, et al. Serum concentrations of gabapentin in cats with chronic kidney disease. Journal of Feline Medicine and Surgery. 2022;24(12):1260-1266. doi:10.1177/1098612X221077017
Quimby JM, Jones SE, Saffire A, et al. Assessment of the effect of gabapentin on blood pressure in cats with and without chronic kidney disease. Journal of Feline Medicine and Surgery. 2024;26(5). doi:10.1177/1098612X241240326
Rusbridge C. Neuropathic pain in cats: mechanisms and multimodal management. Journal of Feline Medicine and Surgery. 2024;26(5). doi:10.1177/1098612X241246518
Siao KT, Pypendop BH, Ilkiw JE. Pharmacokinetics of gabapentin in cats. Am J Vet Res. 2010 Jul;71(7):817-21. doi:10.2460/ajvr.71.7.817
Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med. 2010 Apr;123(4):367-73. doi:10.1016/j.amjmed.2009.09.030
Zour E, Lodhi SA, Nesbitt RU, Silbering SB, Chaturvedi PR. Stability studies of gabapentin in aqueous solutions. Pharm Res. 1992 May;9(5):595-600. doi:10.1023/a:1015833622943
Hill, K., Gieseg, M., Bridges, J., & Chambers, J. (2014). The pharmacokinetics of methimazole in a novel lipophilic formulation administered transdermally to healthy cats. New Zealand Veterinary Journal, 62(4), 208-213. doi:10.1080/00480169.2013.875990
Hill K. E., Chambers J. P., Jones B. R., Bolwell C. F., Aberdein D., Mills P. C. Regional variations in percutaneous absorption of methimazole: an in vitro study on cat skin. J. vet. Pharmacol. Therap. 38, 616-618. doi:10.1111/jvp.12220
Buhles W, Quimby JM, Labelle D, Williams VS. Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. J vet Pharmacol Therap. 2018; 41: 644-651. doi:10.1111/jvp.12691
Fantinati M, Trnka J, Signor A, et al. Appetite-stimulating effect of gabapentin vs mirtazapine in healthy cats post-ovariectomy. Journal of Feline Medicine and Surgery. 2020;22(12):1176-1183. doi:10.1177/1098612X20916391
Ferguson LE, McLean MK, Bates JA, Quimby JM. Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011). Journal of Feline Medicine and Surgery. 2016;18(11):868-874. doi:10.1177/1098612X15599026
Ferro L, Ciccarelli S, Stanzani G, Nappi L, Angelini F, Leo C. Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre Retrospective Study. Animals. 2022; 12(2):155. doi:10.3390/ani12020155
Poole M, Quimby JM, Hu T, Labelle D, Buhles W. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. J vet Pharmacol Therap. 2019; 42: 179-188. doi:10.1111/jvp.12738
Quimby, J.M., Gustafson, D.L. and Lunn, K.F. (2011), The Pharmacokinetics of Mirtazapine in Cats with Chronic Kidney Disease and In Age-Matched Control Cats. J Vet Intern Med, 25: 985-989. doi:10.1111/j.1939-1676.2011.00780.x
Quimby JM, Lunn KF. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J. 2013 Sep;197(3):651-5. doi:10.1016/j.tvjl.2013.05.048
Quimby JM, Benson KK, Summers SC, et al. Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease. Journal of Feline Medicine and Surgery. 2020;22(4):376-383. doi:10.1177/1098612X19851303
Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia. American Journal of Hospice and Palliative Medicine®. 2010;27(2):106-110. doi:10.1177/1049909109345685
Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, Langston C, Lefebvre HP, White J, Quimby J. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016 Mar;18(3):219-39. doi:10.1177/1098612X16631234
Acevedo A, Muñoz KA, Stec M, Pitt K, Jones SA, Manfredi JM. Effect of preoperative ondansetron on postoperative nausea in healthy dogs undergoing laparoscopic gastropexy and castration. Vet Anaesth Analg. 2024 May-Jun;51(3):235-243. doi:10.1016/j.vaa.2024.01.004
Fitzpatrick, R. L., Wittenburg, L. A., Hansen, R. J., Gustafson, D. L., Quimby, J. M. Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. J. vet. Pharmacol. Therap. doi:10.1111/jvp.12286
Hall, E. (2002), Rational selection of gastrointestinal drugs for cats and dogs. In Practice, 24: 242-249. doi:10.1136/inpract.24.5.242
Quimby, J. M., Lake, R. C., Hansen, R. J., Lunghofer, P. J., Gustafson, D. L. Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. J. vet. Pharmacol. Therap. 37, 348-353. doi:10.1111/jvp.12094
Santos LC, Ludders JW, Erb HN, Martin-Flores M, Basher KL, Kirch P. A randomized, blinded, controlled trial of the antiemetic effect of ondansetron on dexmedetomidine-induced emesis in cats. Vet Anaesth Analg. 2011 Jul;38(4):320-7. doi:10.1111/j.1467-2995.2011.00619.x
SEDLACEK, H.S., RAMSEY, D.S., BOUCHER, J.F., EAGLESON, J.S., CONDER, G.A. and CLEMENCE, R.G. (2008), Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. Journal of Veterinary Pharmacology and Therapeutics, 31: 533-537. doi:10.1111/j.1365-2885.2008.00991.x
Trepanier L. Acute Vomiting in Cats: Rational Treatment Selection. Journal of Feline Medicine and Surgery. 2010;12(3):225-230. doi:10.1016/j.jfms.2010.01.005
Hanzlicek AS, Gehring R, Kukanich B, Kukanich KS, Borgarelli M, Smee N, Olson EE, Margiocco M. Pharmacokinetics of oral pimobendan in healthy cats. J Vet Cardiol. 2012 Dec;14(4):489-96. doi:10.1016/j.jvc.2012.06.002
Kittleson MD, Côté E. The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy. Journal of Feline Medicine and Surgery. 2021;23(11):1028-1051. doi:10.1177/1098612X211020162
Oldach MS, Ueda Y, Ontiveros ES, Fousse SL, Harris SP and Stern JA (2019) Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study. Front. Vet. Sci. 6:15. doi:10.3389/fvets.2019.00015
Oldach, M.S., Ueda, Y., Ontiveros, E.S. et al. Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy. BMC Vet Res 17, 89 (2021). doi:10.1186/s12917-021-02799-9
Reina-Doreste Y, Stern JA, Keene BW, Tou SP, Atkins CE, DeFrancesco TC, Ames MK, Hodge TE, Meurs KM. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. J Am Vet Med Assoc. 2014 Sep 1;245(5):534-9. doi:10.2460/javma.245.5.534
Schober KE, Rush JE, Luis Fuentes V, et al. Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. J Vet Intern Med. 2021; 35: 789-800. doi:10.1111/jvim.16054
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. doi:10.1056/NEJMoa011161
Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019; 33: 478-488. doi:10.1111/jvim.15429
Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019; 33: 413-422. doi:10.1111/jvim.15394
Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 Dec;16(12):3631-41. doi:10.1681/ASN.2005050522
Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17):3033-42. doi:10.2174/1381612811319170009
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. doi:10.1056/NEJMoa011303
Sent, U., Gössl, R., Elliott, J., Syme, H.M. and Zimmering, T. (2015), Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med, 29: 1479-1487. doi:10.1111/jvim.13639
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. doi:10.1001/jama.288.19.2421
Hanzlicek AS, Gehring R, Kukanich B, Kukanich KS, Borgarelli M, Smee N, Olson EE, Margiocco M. Pharmacokinetics of oral pimobendan in healthy cats. J Vet Cardiol. 2012 Dec;14(4):489-96. doi:10.1016/j.jvc.2012.06.002
Kittleson MD, Côté E. The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy. Journal of Feline Medicine and Surgery. 2021;23(11):1028-1051. doi:10.1177/1098612X211020162
Oldach MS, Ueda Y, Ontiveros ES, Fousse SL, Harris SP and Stern JA (2019) Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study. Front. Vet. Sci. 6:15. doi:10.3389/fvets.2019.00015
Oldach, M.S., Ueda, Y., Ontiveros, E.S. et al. Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy. BMC Vet Res 17, 89 (2021). doi:10.1186/s12917-021-02799-9
Reina-Doreste Y, Stern JA, Keene BW, Tou SP, Atkins CE, DeFrancesco TC, Ames MK, Hodge TE, Meurs KM. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. J Am Vet Med Assoc. 2014 Sep 1;245(5):534-9. doi:10.2460/javma.245.5.534
Schober KE, Rush JE, Luis Fuentes V, et al. Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. J Vet Intern Med. 2021; 35: 789-800. doi:10.1111/jvim.16054